Novo Nordisk Streamlines Metabolism Focus as Menopause Data and Analyst Upgrade Signal Turnaround
Novo Nordisk sheds last cell therapy asset to focus on metabolic diseases, as Hedgeye predicts 52-117% upside and…
Menopause Heart Data, Oral Pill Revenue Double, and a Parkinso
Novo Nordisk: Wegovy CV risk reduction 42% in perimenopausal women, oral pill sales double forecasts, high-dose 27.7% weight…
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10…